Tags

Type your tag names separated by a space and hit enter

Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma.
Cancer. 2005 Oct 15; 104(8):1668-77.C

Abstract

BACKGROUND

Vascular endothelial growth factor-C (VEGF-C) plays an important role in lymphangiogenesis and activates VEGF receptor-3 (VEGFR-3). Lymphatic spread is an important prognostic factor in patients with lung adenocarcinoma. The aim of the current study was to determine whether the expression of VEGF-C and VEGFR-3 correlates with clinicopathologic factors and prognosis in patients with TNM classification T1 lung adenocarcinoma.

METHODS

The authors conducted a retrospective review of 129 consecutive patients who underwent complete resection for T1 lung adenocarcinoma. Immunohistochemical staining for VEGF-C, VEGF, VEGFR-3, CD34 (microvessels), tryptase (mast cells), and CD68 (macrophages) was performed to statistically analyze clinicopathologic implications of VEGF-C and VEGFR-3 status.

RESULTS

Of 129 patients with T1 lung adenocarcinoma, 56 (43.3%) patients were positive for tumor-cell VEGF-C and 73 (56.6%) and 69 (53.5%) patients were positive for tumor-cell and endothelial-cell VEGFR-3, respectively. Patients with positive staining for tumor-cell VEGF-C showed significantly less favorable survival rates than patients with negative staining (P = 0.031). The survival rates of patients with positive staining for tumor-cell and endothelial-cell VEGFR-3 were significantly lower than those with negative staining (P = 0.0034 and P = 0.0020, respectively). Patients with positive staining for both tumor-cell VEGF-C and endothelial-cell VEGFR-3 exhibited the most unfavorable prognoses. Multivariate analysis demonstrated that coexpression of tumor-cell VEGF-C and endothelial-cell VEGFR-3 was an independent negative prognostic factor (P = 0.0129) as well as N factor (P = 0.0020).

CONCLUSIONS

VEGF-C and VEGFR-3 status may be indicative of survival rates for patients with T1 lung adenocarcinoma.

Authors+Show Affiliations

Department of Respiratory Medicine, Obihiro Kyokai Hospital, Obihiro, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

16116610

Citation

Kojima, Hiroshi, et al. "Clinical Significance of Vascular Endothelial Growth factor-C and Vascular Endothelial Growth Factor Receptor 3 in Patients With T1 Lung Adenocarcinoma." Cancer, vol. 104, no. 8, 2005, pp. 1668-77.
Kojima H, Shijubo N, Yamada G, et al. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer. 2005;104(8):1668-77.
Kojima, H., Shijubo, N., Yamada, G., Ichimiya, S., Abe, S., Satoh, M., & Sato, N. (2005). Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer, 104(8), 1668-77.
Kojima H, et al. Clinical Significance of Vascular Endothelial Growth factor-C and Vascular Endothelial Growth Factor Receptor 3 in Patients With T1 Lung Adenocarcinoma. Cancer. 2005 Oct 15;104(8):1668-77. PubMed PMID: 16116610.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. AU - Kojima,Hiroshi, AU - Shijubo,Noriharu, AU - Yamada,Gen, AU - Ichimiya,Shingo, AU - Abe,Shosaku, AU - Satoh,Masaaki, AU - Sato,Noriyuki, PY - 2005/8/24/pubmed PY - 2006/1/13/medline PY - 2005/8/24/entrez SP - 1668 EP - 77 JF - Cancer JO - Cancer VL - 104 IS - 8 N2 - BACKGROUND: Vascular endothelial growth factor-C (VEGF-C) plays an important role in lymphangiogenesis and activates VEGF receptor-3 (VEGFR-3). Lymphatic spread is an important prognostic factor in patients with lung adenocarcinoma. The aim of the current study was to determine whether the expression of VEGF-C and VEGFR-3 correlates with clinicopathologic factors and prognosis in patients with TNM classification T1 lung adenocarcinoma. METHODS: The authors conducted a retrospective review of 129 consecutive patients who underwent complete resection for T1 lung adenocarcinoma. Immunohistochemical staining for VEGF-C, VEGF, VEGFR-3, CD34 (microvessels), tryptase (mast cells), and CD68 (macrophages) was performed to statistically analyze clinicopathologic implications of VEGF-C and VEGFR-3 status. RESULTS: Of 129 patients with T1 lung adenocarcinoma, 56 (43.3%) patients were positive for tumor-cell VEGF-C and 73 (56.6%) and 69 (53.5%) patients were positive for tumor-cell and endothelial-cell VEGFR-3, respectively. Patients with positive staining for tumor-cell VEGF-C showed significantly less favorable survival rates than patients with negative staining (P = 0.031). The survival rates of patients with positive staining for tumor-cell and endothelial-cell VEGFR-3 were significantly lower than those with negative staining (P = 0.0034 and P = 0.0020, respectively). Patients with positive staining for both tumor-cell VEGF-C and endothelial-cell VEGFR-3 exhibited the most unfavorable prognoses. Multivariate analysis demonstrated that coexpression of tumor-cell VEGF-C and endothelial-cell VEGFR-3 was an independent negative prognostic factor (P = 0.0129) as well as N factor (P = 0.0020). CONCLUSIONS: VEGF-C and VEGFR-3 status may be indicative of survival rates for patients with T1 lung adenocarcinoma. SN - 0008-543X UR - https://www.unboundmedicine.com/medline/citation/16116610/Clinical_significance_of_vascular_endothelial_growth_factor_C_and_vascular_endothelial_growth_factor_receptor_3_in_patients_with_T1_lung_adenocarcinoma_ DB - PRIME DP - Unbound Medicine ER -